BACE1 and early-onset autosomal dominant Alzheimer disease: As a promising therapeutic target for the treatment of Alzheimer’s disease, understanding the detailed mechanism underlying the pH dependence of BACE-1 dynamics and enzymatic activity is imperative for structure-based drug design.